Skip to Content

Clarity Pharmaceuticals Ltd - Stock Quote CU6

Rating as of

Morningstar's Clarity Pharmaceuticals Ltd Stock Analysis

Currency in AUD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Clarity Pharmaceuticals Ltd's Company Profile

Business Description

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

2-4 Cornwallis Street, National Innovation Centre, Suite 212a
Sydney, NSW, 2015, Australia
T +61 292094037
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type